Info

A balanced overview of the research behind every compound in the range.

Peptides are short chains of amino acids that act as signalling molecules in the body. Some peptides are used in approved medicines, while others are still being studied for areas such as metabolism, recovery, skin quality, body composition and healthy ageing.

The science behind peptides is genuinely interesting, but the evidence is not the same for every compound. Some, such as semaglutide, tirzepatide and tesamorelin, have strong human clinical research behind them. Others, such as BPC-157, TB-500, MOTS-c and GHK-Cu, are more research-forward, with promising mechanisms but less settled human evidence.

This page gives a practical, balanced overview of the current research so customers can understand what each peptide is commonly studied for.

What are peptides?

Peptides are small chains of amino acids. Amino acids are the same building blocks that make up proteins, but peptides are shorter and often act more like biological messengers.

Different peptides interact with different pathways. Some influence appetite and blood sugar signalling. Others are studied for tissue repair, skin quality, mitochondrial function, growth hormone signalling or metabolic health.

The positive side of peptide research is that peptides can be very targeted. Instead of acting broadly across the body, many are designed to interact with specific receptors or biological systems. That is why peptide-based medicines have become important in areas such as diabetes, obesity, hormone research and regenerative medicine.

How strong is the evidence?

Not all peptides sit at the same level of research.

Some products have strong clinical evidence and approved medical uses. Semaglutide and tirzepatide are well-studied GLP-1 or incretin-based medicines used in weight management and metabolic health. Tesamorelin is approved for reducing excess abdominal fat in adults with HIV-associated lipodystrophy.

Other peptides are earlier in the research journey. BPC-157, TB-500, CJC-1295 with DAC, ipamorelin, MOTS-c and injectable GHK-Cu have interesting mechanisms and positive early research signals, but they should not be described as guaranteed treatments.

The most honest way to look at them is simple: some are clinically established, while others are promising but still developing.

BPC-157

BPC-157 is a synthetic peptide based on a protective compound found in the stomach. It is often discussed in research around tissue repair, gut protection, tendon healing, ligament recovery and inflammation control.

The most positive part of the BPC-157 story is its broad preclinical interest. Animal and laboratory studies suggest that it may support blood vessel formation, fibroblast activity, collagen signalling and repair processes. This is why it has become popular in the recovery and injury-support space.

The balanced view is that most of the evidence is still preclinical. Human data is limited, and BPC-157 is not an approved medicine in major regulated markets. It is best positioned as a research-forward recovery peptide rather than a proven clinical treatment.

TB-500

TB-500 is commonly associated with thymosin beta-4, a naturally occurring peptide involved in cell migration, tissue repair and wound healing pathways.

The positive outlook is that thymosin beta-4 has a strong research background in tissue regeneration, wound repair and healing response. This gives TB-500 an attractive recovery-focused narrative, especially for people interested in mobility, soft-tissue support and repair signalling.

The important distinction is that much of the strongest published evidence relates to full-length thymosin beta-4, not always the TB-500 fragment sold in wellness and research markets. Because of that, TB-500 should be positioned carefully as thymosin-beta-4-inspired recovery research, not as a guaranteed healing product.

CJC-1295 with DAC

CJC-1295 with DAC is a modified growth-hormone-releasing hormone analogue. It is designed to stimulate the body's own growth hormone and IGF-1 signalling pathway over a longer period.

Its strongest positive angle is the mechanism. Rather than replacing growth hormone directly, CJC-1295 works upstream by encouraging growth hormone release. Early human studies showed sustained increases in growth hormone and IGF-1 after administration.

The balanced view is that it remains investigational. It is not an approved body-composition or anti-ageing medicine, and regulatory reviews have raised safety questions around long-term use. It is best described as an advanced GH-axis research peptide with interesting physiology but incomplete clinical certainty.

Ipamorelin

Ipamorelin is a growth hormone secretagogue. It works through the ghrelin receptor and is studied for its ability to stimulate growth hormone release.

The positive side of ipamorelin is selectivity. Early research suggested it may stimulate growth hormone without strongly increasing cortisol or ACTH, which made it attractive compared with older growth hormone secretagogues.

The balanced view is that long-term human clinical evidence is still limited. It has biological activity, but it does not have an approved mainstream indication for body composition, recovery or anti-ageing. It is best positioned as a selective GH-secretagogue research peptide.

Tesamorelin

Tesamorelin has one of the strongest clinical foundations in the peptide category. It is an FDA-approved growth-hormone-releasing hormone analogue used to reduce excess abdominal fat in adults with HIV-associated lipodystrophy.

The positive outlook is clear: tesamorelin has human clinical data behind it, especially around visceral fat reduction. Research has also explored its effect on liver fat and body composition in specific patient groups.

The balanced view is that tesamorelin is not a general fat-loss peptide. Its approved use is specific, and it has a more serious medical profile than casual wellness products. That makes it credible, but it should be described accurately.

MOTS-c

MOTS-c is a mitochondrial-derived peptide. It is studied for its possible role in metabolism, insulin sensitivity, exercise response and healthy ageing research.

The positive angle is that MOTS-c connects to one of the most exciting areas in modern health science: mitochondrial signalling. Preclinical studies suggest links to glucose metabolism, energy balance, exercise performance and metabolic stress response.

The balanced view is that MOTS-c is still early-stage. There is no approved medical use, no standard clinical dosing framework and limited completed human outcome data. It is best positioned as an emerging mitochondrial-performance peptide with promising research, not as a proven longevity treatment.

GHK-Cu

GHK-Cu is a copper-binding peptide naturally found in the body. It is best known for research around skin quality, wound support, collagen, elastin and tissue remodelling.

The positive side is strong in the skin and regenerative aesthetics space. Research links GHK-Cu to collagen production, elastin support, glycosaminoglycan synthesis, wound-healing pathways and visible skin-quality improvements.

The balanced view is that the strongest evidence is mainly topical and cosmetic. Injectable use is less settled. GHK-Cu is best positioned around skin quality, tissue renewal and regenerative-aesthetic research rather than broad anti-ageing claims.

Semaglutide

Semaglutide is a GLP-1 receptor agonist. It is one of the strongest evidence-backed products in the category and is widely studied for appetite regulation, weight management, blood sugar control and cardiometabolic health.

The positive outlook is strong. Large clinical trials show meaningful weight reduction, and additional research has shown cardiovascular benefit in adults with overweight or obesity and established cardiovascular disease.

The balanced view is that semaglutide is still a medical product, not a casual wellness supplement. It can cause gastrointestinal side effects, requires careful titration and has specific contraindications. Still, from an evidence perspective, it is one of the most clinically validated products in the catalogue.

Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist. It is used in metabolic medicine and has strong clinical data for weight management and blood sugar improvement.

The positive outlook is very strong. In clinical trials, tirzepatide produced substantial weight reduction, with some studies showing results approaching the upper end of what is currently seen in non-surgical obesity medicine.

The balanced view is that tirzepatide is still a prescription-level medicine in regulated markets. It needs gradual dose escalation, can cause gastrointestinal side effects and is not suitable for everyone. It should be positioned as a high-evidence metabolic product rather than a quick-fix weight-loss shortcut.

Retatrutide

Retatrutide is an investigational triple agonist that targets GIP, GLP-1 and glucagon receptors. It is one of the most interesting future-facing compounds in metabolic research.

The positive outlook is significant. Phase 2 research showed substantial weight reduction, and its triple-receptor mechanism makes it one of the most advanced concepts in the obesity and metabolic-health pipeline.

The balanced view is essential: retatrutide is not currently approved by major regulators and is legally available only through clinical trials in many jurisdictions. It should be described as next-generation metabolic research, not as an established commercial medicine.

Peptide stacks

Peptide stacks are combinations built around a specific goal, such as metabolic support, recovery, skin quality or body-composition research.

The idea behind stacking is that different peptides may target different pathways. For example, one product may focus on appetite regulation, while another may focus on recovery signalling or skin-quality research.

The balanced view is that stacking is common commercially, but the evidence is usually thinner than the evidence for individual approved medicines. Stacks should therefore be framed as curated combinations based on mechanism and research interest, not guaranteed outcomes.

A responsible stacks page should make the goal clear, explain why each product is included, and avoid overpromising results.

Responsible use and expectations

Peptide research is moving quickly, but responsible expectations matter.

Some peptides have strong clinical evidence. Others are promising but still early. A credible peptide brand should explain the difference clearly instead of making every product sound equally proven.

Customers should also understand that some peptides may be prescription medicines, investigational compounds or prohibited in tested sport. Anyone with existing medical conditions, pregnancy plans, diabetes, cancer history, gallbladder disease, pancreatitis history or competitive-sport obligations should seek qualified medical guidance before use.

This does not make peptides uninteresting. It simply means the best approach is informed, careful and evidence-aware.